ST.
PAUL, Minn., Sept. 16,
2024 /PRNewswire/ -- ScaleReady and Bio-Techne
Corporation (NASDAQ: TECH) today announced the launch of the G-Rex
optimized ProPakTM GMP Cytokines, ideally tailored to
high efficiency closed system cell and gene-modified cell therapy
(CGT) manufacturing.
The ProPakTM GMP Cytokine product consists of a
weldable bag filled with liquid formulated GMP-grade cytokines,
specifically interleukin-7 (IL-7) or interleukin-15 (IL-15),
commonly used in the ex vivo manufacturing of CAR-T and TCR-T
cells. The quantity of IL-7 and IL-15 contained in each
ProPakTM is sufficient to dose a one (1) liter G-Rex
bioreactor at the recommended 10ng/mL concentration. The use
of ProPak GMP cytokines will enable manufacturers of CAR-T and
TCR-T cell therapies to reduce operating costs and complexity by
dramatically simplifying the process of acquiring, storing,
preparing, and administering these critical reagents for use in
cGMP manufacturing.
"Bio-Techne is deeply committed to highly efficient manufacture
of lifesaving cell and gene-modified cell therapies," said
Will Geist, President (Protein
Sciences) at Bio-Techne Corporation. "ProPakTM GMP
Cytokines were optimized for use with the leading G-Rex platform by
providing the precise quantity of cytokines needed for highly
simplified closed system expansion of CAR-T and TCR-T cell drug
products with excellent cell characteristics."
"The G-Rex optimized ProPakTM GMP Cytokine is a
differentiated product as it is uniquely designed to enable users
of G-Rex to manufacture CAR-T and TCR-T drug products with far more
simplicity than is possible with any other cytokine vendor," said
Josh Ludwig, Global Commercial
Director at ScaleReady. "It eliminates the need for cytokine
reconstitution and all of the related headaches in favor of a
hands-off ballroom style G-Rex manufacturing approach.
"With the incredible response to our G-Rex Grant Program moving
G-Rex into the majority of CGT clinical trials, the G-Rex optimized
ProPak is the perfect next step in G-Rex manufacturing simplicity.
Grant applicant or not, we will help every G-Rex user cost
effectively perform comparability studies to integrate the
ProPak GMP Cytokines," concluded Josh
Ludwig.
Parties interested in learning more and/or evaluating the
ProPakTM GMP Cytokines can reach out to
info@scaleready.com .
About ScaleReady
ScaleReady provides the field of cell
and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
CGT entities that rely on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
The G-Rex manufacturing platform is now used in 50% of clinical
trials and by over 800 organizations producing drug products
expected to move well into the majority of clinical trials as a
result of the ScaleReady G-Rex Grant Program. G-Rex is also
currently used to make 4 commercially approved CGT drugs; 3
autologous and 1 allogeneic.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to
G-Rex® Bioreactors, including right-sized reagent quantities in
containers that are tailored to high throughput closed-system
manufacturing. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the Company
on social media at: Facebook, LinkedIn, Twitter or
YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-and-bio-techne-announce-optimal-closed-system-cytokine-packaged-for-single-step-use-in-closed-system-g-rex-manufacture-of-car-t-and-tcr-therapies-302248409.html
SOURCE Bio-Techne Corporation
